Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Barbara Ann Karmanos Cancer Institute
Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Description
OBJECTIVES: Primary * Evaluate the use of 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer. Secondary * Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment. OUTLINE: Patients undergo up to four 3'-deoxy-3'-\[18F\] fluorothymidine positron emission tomography imaging procedures.
Eligibility
- Age range
- 18–120 years
- Sex
- All
- Healthy volunteers
- No
DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Histologically confirmed solid tumor or hematologic malignancy * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging PATIENT CHARACTERISTICS: * Able to lie still in the PET scanner * Girth and weight must be suitable to enter the gantry * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * Not specified
Interventions
- Device3'-deoxy-3'-[18F]fluorothymidine
The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Location
- Barbara Ann Karmanos Cancer InstituteDetroit, Michigan